Empagliflozin ‘staves off hospital for patients with true HFpEF’
Fresh analysis of a pivotal heart failure trial highlights the drug's benefit in patients with a high degree of ejection fraction preservation
New data from a ground-breaking empagliflozin heart failure trial bolsters claims that the sodium-glucose transport protein 2 inhibitor keeps patients with preserved ejection fraction out of hospital for longer, the authors say.
The EMPEROR-Preserved randomised controlled trial of nearly 6000 patients was the first to show the drug reduced hospitalisation for heart failure in patients (mean age 72) with a left ventricular ejection fraction (LVEF) above 40%, regardless of diabetes.
